Savan spent the majority of his 15 year career in the Life Sciences industry working with hundreds of public and private corporations as a Healthcare Investment Banker at Citigroup, Deutsche Bank. From Analyst through Managing Director, he led ~40 financing, IPO, and M&A deals, totaling $35+ billion in deal value, and experienced many invaluable business and scientific lessons from his work with clients across the spectrum of drug, diagnostic, and device technologies such as Amgen, Anacor, Boston Scientific, Eli Lilly, Intermune, Map Pharma, Masimo, Medtronic, Omeros, Pacific Biosciences, and many others. While a Vice President at Deutsche Bank, Savan was selected to lead the firm's build-out of its Healthcare business into Asia, leading to IPO's of the two largest healthcare companies in China, Shanghai Pharma and Fosun Pharma. Savan began his career as a Bioengineer at Life Technologies.
Savan graduated with a M.S.E. in Bioengineering from the University of Pennsylvania, with an emphasis in Business from Wharton and a B.S.E. in Bioengineering focused in Computer Science from the University of California at Berkeley.
After many years of academic and professional experience in the healthcare field, a deeply personal experience later in life gave Savan a new perspective into how much healthcare needed to change – his mother was abruptly diagnosed with stage IVb cancer. This compelled Savan to ask “where were all the signs” and “isn't there a better way,” which led to BioTrillion.
Sunil brings over 20 years of biotech management and R&D experience, with significant emphasis on dealmaking to enable value creation from innovation. Most recently, he was EVP & CFO of OncoMed Pharmaceuticals (NASDAQ: OMED), a cancer therapeutics company. He is also currently a member of the Board of Directors of Ligand Pharmaceuticals (NASDAQ: LGND). Sunil has also held roles in finance, business development, and marketing, including positions with OncoMed, BiPar, Allos, Connetics, Abgenix, and Gilead. Earlier in his career, he was with McKinsey & Company advising both biotech and high tech companies. Sunil started his career in the lab, including working as an analytical protein chemist with ZymoGenetics. He is passionate about leveraging novel technologies to improve healthcare, with a particular interest in opportunities at the intersection of the revolutions taking place in IT and biotech.
Sunil graduated with a M.S. in Molecular Bioengineering from the University of Washington and a B.S. in Chemistry from the University of California at Berkeley.
Jordan Shlain is a medical doctor dedicated to proving that data-driven, proactive primary care can prevent unnecessary specialty care and improve longevity. An internist and an entrepreneur, Dr. Shlain founded Private Medical, a family office for health and medicine in 2002. Private Medical is a by-invitation-only, full-service, multi-generational medical practice, with offices in San Francisco, Silicon Valley, Beverly Hills, and New York. Private Medical has discreet relationships with elite medical institutions and experts, nationally and internationally. Earlier in his career, Dr. Shlain was appointed San Francisco Health Commissioner by the Mayor of San Francisco after having been elected as the youngest physician to the board of the San Francisco Medical Society. He has been involved with healthcare policy at the state and national level. He is a frequent guest professor at Princeton, Columbia, Mt. Sinai, and UC Berkeley. Dr. Shlain was recently featured on the front page of the New York Times Business section as a thought leader and trail blazer in the emerging field of private medicine.
Jordan Shlain studied Anatomy and Physiology @ UC Berkeley and received his Medical Degree @ Georgetown University Medical School, subsequently completing his clinical training at California Pacific Medical Center with UCSF.
Dr. Liebman brings over four decades of experience in Life Sciences from both industry and academia. Among just a few notable positions he has held, include: Chief Scientific Officer at the Chan Soon-Shiong Institute of Molecular Medicine at Windber; Director of Computational Biology and Global Head of Computational Genetics at Roche; Director of Biomedical Informatics and Pharmacogenomics and Director of Bioinformatics Discovery Research at Wyeth; Advisory Board at the American Heart Association; Professor in the Department of Physiology and Biophysics at Mount Sinai School of Medicine; Professor in the Department of Cancer Biology at the University of Pennsylvania; and many others. He has also been an Advisor and Consultant to many private life sciences companies who have gone on to make an impact in the Healthcare industry.
Dr. Liebman completed his Research Fellowship in Physiological Chemistry, Post-Doctorate in Biochemistry, PhD in Biochemistry, and B.S. in Physical Chemistry.
Dr. Fontanella brings tremendous clinical experience from his years at the prestigious Memorial Sloan Kettering Cancer Center, as both a data science researcher and as Chief Resident in Medical Physics. Throughout his 10+ years of experience in a healthcare environment, he has developed a passion for developing quantitative methods for improving cancer patients’ treatment outcomes. His personal experiences of seeing close family members bravely battling deadly diseases has sparked a deep drive within him to apply his knowledge and experience towards the improvement of healthcare in the US through advanced machine learning techniques.
Dr. Fontanella graduated with a PhD in Biomedical Engineering from Duke University while studying under the mentorship of Mark Dewhirst, a renowned leader in the field of tumor microcirculation and targeted drug delivery. His thesis work involved in vivo observation of vascular radiation-response in tumors using optical techniques. He also holds a Masters degree in Electrical and Computer Engineering, with a focus in Optics, Photonics, and Image Processing.